Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis
Journal of Cachexia, Sarcopenia and Muscle · 2024-06 · 15 (3) · 975-988
DOI: 10.1002/jcsm.13466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 17.04.2024. Verfasst von Paige C Arneson-Wissink und 8 weiteren Autor:innen. Beteiligte Einrichtung: Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA. Hauptthemen laut MEDLINE: Cachexia, STAT3 Transcription Factor, Pancreatic Neoplasms, Signal Transduction. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Brenden-Colson Center for Pancreatic Care, Oregon Pancreas Tissue Registry.
Abstract (Originalsprache)
Background
Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are poorly defined. During periods of nutritional scarcity, the body relies on hepatic ketogenesis to generate ketone bodies, and lipid metabolism via ketogenesis is thought to protect muscle from catabolizing during nutritional scarcity.
Methods
We developed an orthotopic mouse model of early PDAC cachexia in 12‐week‐old C57BL/6J mice. Murine pancreatic cancer cells (KPC) were orthotopically implanted into the pancreas of wild‐type, IL‐6 −/− , and hepatocyte STAT3 −/− male and female mice. Mice were subject to fasting, 50% food restriction, ad libitum feeding or ketogenic diet interventions. We measured longitudinal body composition by EchoMRI, body mass and food intake. At the endpoint, we measured tissue mass, tissue gene expression by quantitative real‐time polymerase chain reaction, whole‐body calorimetry, circulating hormone levels, faecal protein and lipid content, hepatic lipid content and ketogenic response to medium‐chain fatty acid bolus. We assessed muscle atrophy in vivo and C2C12 myotube atrophy in vitro.
Results
Pre‐cachectic PDAC mice did not preserve gastrocnemius muscle mass during 3‐day food restriction (−13.1 ± 7.7% relative to food‐restricted sham, P = 0.0117) and displayed impaired fatty acid oxidation during fasting, resulting in a hypoketotic state (ketogenic response to octanoate bolus, −83.0 ± 17.3%, P = 0.0328; Hmgcs2 expression, −28.3 ± 7.6%, P = 0.0004). PDAC human patients display impaired fasting ketones (−46.9 ± 7.1%, P < 0.0001) and elevated circulating interleukin‐6 (IL‐6) (12.4 ± 16.5‐fold increase, P = 0.0001). IL‐6 −/− PDAC mice had improved muscle mass (+35.0 ± 3.9%, P = 0.0031) and ketogenic response (+129.4 ± 44.4%, P = 0.0033) relative to wild‐type PDAC mice. Hepatocyte‐specific signal transducer and activator of transcription 3 (STAT3) deletion prevented muscle loss (+9.3 ± 4.0%, P = 0.009) and improved fasting ketone levels (+52.0 ± 43.3%, P = 0.018) in PDAC mice. Without affecting tumour growth, a carbohydrate‐free diet improved tibialis anterior myofibre diameter (+16.5 ± 3.5%, P = 0.0089), circulating ketone bodies (+333.0 ± 117.6%, P < 0.0001) and Hmgcs2 expression (+106.5 ± 36.1%, P < 0.0001) in PDAC mice. Ketone supplementation protected muscle against PDAC‐induced atrophy in vitro (+111.0 ± 17.6%, P < 0.0001 myofibre diameter).
Conclusions
In early PDAC cachexia, muscle vulnerability to wasting is dependent on inflammation‐driven metabolic reprogramming in the liver. PDAC suppresses lipid β‐oxidation and impairs ketogenesis in the liver, which is reversed in genetically modified mouse models deficient in IL‐6/STAT3 signalling or through ketogenic diet supplementation. This work establishes a direct link between skeletal muscle homeostasis and hepatic metabolism. Dietary and anti‐inflammatory interventions that restore ketogenesis may be a viable preventative approach for pre‐cachectic patients with pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA.
- Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, USA.
- Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, USA.
ORCID-Profile: Paige C Arneson-Wissink, Aaron J Grossberg
Förderung
- NCI NIH HHS
- Brenden-Colson Center for Pancreatic Care
- Oregon Pancreas Tissue Registry
- Oregon Health and Science University
- National Cancer Institute
Zitieren
APA
Arneson-Wissink, P. C., Mendez, H., Pelz, K., Dickie, J., Bartlett, A. Q., Worley, B. L., Krasnow, S. M., Eil, R., & Grossberg, A. J. (2024). Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis. Journal of Cachexia, Sarcopenia and Muscle, 15(3), 975-988. https://doi.org/10.1002/jcsm.13466
Vancouver
Arneson-Wissink PC, Mendez H, Pelz K, Dickie J, Bartlett AQ, Worley BL, et al. Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(3):975-988. doi:10.1002/jcsm.13466
BibTeX
@article{ArnesonWissink2024,
author = {Arneson-Wissink, Paige C and Mendez, Heike and Pelz, Katherine and Dickie, Jessica and Bartlett, Alexandra Q and Worley, Beth L and Krasnow, Stephanie M and Eil, Robert and Grossberg, Aaron J},
title = {Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
volume = {15},
number = {3},
pages = {975--988},
doi = {10.1002/jcsm.13466}
}
EUVIMED